HUTCHMED (China) Limited (HCM)
NASDAQ: HCM · Real-Time Price · USD
17.77
+0.18 (1.02%)
At close: Jul 21, 2025, 4:00 PM
17.74
0.00 (0.00%)
Pre-market: Jul 22, 2025, 7:00 AM EDT
HUTCHMED (China) Employees
HUTCHMED (China) had 1,811 employees as of December 31, 2024. The number of employees decreased by 177 or -8.90% compared to the previous year.
Employees
1,811
Change (1Y)
-177
Growth (1Y)
-8.90%
Revenue / Employee
$347,985
Profits / Employee
$20,833
Market Cap
2.93B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
HCM News
- 19 days ago - HUTCHMED to Announce 2025 Half-Year Financial Results - GlobeNewsWire
- 22 days ago - HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy - GlobeNewsWire
- 6 weeks ago - HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma - GlobeNewsWire
- 7 weeks ago - HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting - GlobeNewsWire
- 2 months ago - HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting - GlobeNewsWire
- 3 months ago - HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025 - GlobeNewsWire
- 3 months ago - HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China - GlobeNewsWire
- 4 months ago - HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma - GlobeNewsWire